Ozempic prospects to further power Novo Nordisk growth

16 May 2023

Much has been made of the sudden rise in sales of Wegovy (semaglutide) and the weight loss drug’s impact in driving rapid growth at Novo Nordisk (NOV: N).

But Ozempic - another usage of semaglutide, this time for treating type 2 diabetes and preventing major cardiovascular problems and with a lower maximum dose - is also forecast to deliver the Danish company a healthy sales boost.

Ozempic is predicted to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position as the dominant market leader, as projected sales will be 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly (NYSE: LLY), which anticipates sales of $8 billion, says GlobalData, the data and analytics company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK